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Abstract
Nocturnal frontal lobe epilepsy has been historically considered a channelopathy caused by mutations in subunits of the
neuronal nicotinic acetylcholine receptor or in a recently reported potassium channel. However, these mutations account
for only a minority of patients, and the existence of at least a new locus for the disease has been demonstrated. In 2005, we
detected two nucleotide variations in the promoter of the CRH gene coding for the corticotropin releasing hormone in 7
patients. These variations cosegregated with the disease and were demonstrated to alter the cellular levels of this hormone.
Here, we report the identification in an Italian affected family of a novel missense mutation (hpreproCRH p.Pro30Arg)
located in the region of the CRH coding for the protein pro-sequence. The mutation was detected in heterozygosity in the
two affected individuals. In vitro assays demonstrated that this mutation results in reduced levels of protein secretion in the
short time thus suggesting that mutated people could present an altered capability to respond immediately to stress
agents.
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Introduction
Nocturnal frontal lobe epilepsy (NFLE) is an idiopathic partial
epilepsy with increased nocturnal instability, first described in
1994 [1]. It is characterized by a wide spectrum of stereotyped
motor manifestations of increasing complexity, ranging from brief
motor events to major episodes, mostly occurring during non-
REM sleep. NFLE, as well as the familial form of the disease
named ADNFLE (Autosomal Dominant NFLE)(OMIM
#600513;%603204; #605375; #610353), generally develops
within the first two decades of life and frequently disappears in
adulthood [2]. Until now 12 mutations affecting genes coding for
different subunits (a2, a4 and b2) of the neuronal nicotinic
acetylcholine receptor (nAChR) have been associated with the
pathogenesis of the disease [2]. However, these mutations account
for a minority of patients and the existence of additional loci was
demonstrated [3]. Very recently, 4 mutations, causing a more
severe form of ADNFLE with intellectual disability and psychiatric
features, have been detected in the KNCT1 gene (OMIM
*608167) encoding a sodium-gated potassium channel subunit
[4]. Finally, in a group of NFLE patients we detected two
nucleotide variations in the promoter region of the CRH gene
(OMIM *122560) co-segregating with the disease and affecting the
gene expression, thus suggesting a possible role in the disease
pathogenesis [5,6]. This gene encodes for the Corticotropin-
releasing hormone (CRH), a 41-amino acid peptide derived from a
196-amino acid preprohormone and widely distributed through-
out the central nervous system [7–9]. CRH acts as a neurotrans-
mitter or neuromodulator in extrahypothalamic circuits to
integrate a multisystem response to stress that controls numerous
behaviours such as locomotor activity, anxiety, food intake, sexual
behaviour, sleep, arousal and learning [10–12].
To increase our knowledge on the role of CRH in ADNFLE, we
performed a mutation screening of the CRH gene in an Italian
family showing a typical form of ADNFLE without psychiatric
comorbidities (thus excluding an involvement of the KCNT1 gene)
and where mutations in the nAChR genes were excluded.
Here, we report, in this family, the identification of a novel
missense mutation (hpreproCRH p.Pro30Arg) located in the
region of the CRH coding for the protein pro-sequence. The
mutation was detected in heterozygosity in the two affected
individuals. In vitro assays demonstrated that this mutation results
in reduced levels of protein secretion in the short time thus
suggesting that mutated people could present an altered capability
to response immediately to stress agents.
Materials and Methods
Sample composition
The sample is composed by an Italian family showing two cases
of ADNFLE and a case of spina bifida (Fig. 1). Since the age of 10
years, the family proband had recurrent nocturnal episodes,
characterized by a sudden elevation of head and trunk, frequently
associated with bimanual and bipedal motor activity. Episodes
occurred every night, more frequently in the first third of the
night, lasting from 15 to more than 60 sec. Sometimes (4–5
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times/month) after the arousal, he would get out of the bed and
start wandering around, jumping and making puppet-like move-
ments with his arms. He had no memory of the episodes.
Neurological examination and magnetic resonance imaging
(MRI) were normal. Video-polysomnography showed two epi-
sodes characterized by an arousal with a sudden elevation of head
and trunk and tonic/dystonic posture of the arms: one episode was
from stage 2 NREM sleep, and the second one from Slow Wave
Sleep. Sleep EEG showed ictal rhythmic slow activity over frontal
areas.
The patient has been treated by levetiracetam; with the dose of
1,000 mg at bedtime, the nocturnal seizures were greatly reduced
in frequency and complexity.
The sister of the proband experienced similar nocturnal
episodes from age 11: until the age of 28, the episodes occurred
almost every night (2–3 times/night) and afterwards the frequency
was reduced (1–2 episodes/month). She had twin daughters one of
which affected by spina bifida.
A group of 100 healthy controls, selected by means of an absent
clinical history for the more common diseases and for epilepsy and
sleep disorders, was also considered in the study. All individuals
were adult and the sex ratio was 1:1.
The study was approved by an institutional ethical committee (S
Raffaele Hospital, Milano, Italy). Written informed consent was
obtained from all participants in the study. The study did not
involved children/minors.
Mutation Detection
Polymerase chain reactions (PCRs) were performed directly on
genomic DNA. The reaction mixture was prepared according to
the protocol of the GoTaq Master Mix (Promega, Madison, WI,
USA). PCRs were performed under standard conditions. Primers
(Sigma Aldrich St. Louis, MO, USA) were designed from the
known genomic sequence of the CRH gene and by means of the
Oligo 6.0 software (Molecular Biology Insights Inc, Cascade, CO,
USA). Primer sequences are available on request. Sequencing
reactions, performed directly on purified PCR products, were
performed on both strands by means of the BigDye Terminator
Cycle Sequencing kit v1.1 and an automated ABI-3100 DNA
sequencer (Applied Biosystems, Foster City, CA, USA). Chroma-
sPro v1.34 (Technelysium Ltd., South Brisbane, Australia)
software was used for mutation detection. Sequences were
compared with the GenBank sequence NG_016127.1.
Plasmid constructs and expression vectors
An IMAGE full length human CRH cDNA clone
(IRAUup969F078D) cloned into pOTB7 plasmid was purchased
by Source Bioscience LifeSciences (Nottingham, UK).
Quick Change II XL Site Directed Mutagenesis Kit (Strata-
gene, La Jolla, CA, USA) was used to introduce the CRH
mutation (c. 89C.G). The cDNA was completely resequenced
after mutagenesis to confirm the presence of the desired mutation
and to exclude the introduction of other undesired DNA
variations.
Plasmids containing the wild-type or the mutated cDNA were
purified using the QIAGEN Plasmid Maxiprep kit (QIAGEN,
Hilden, Germany) following the suggested protocol and resus-
pended in water.
Wild-type and mutant cDNAs were then subcloned into the
pcDNA3.1 vector, previously cut with EcoRI and XhoI. DNA
sequencing confirmed the expected sequence of all constructs.
Cell cultures and transfection
CRH protein expression and secretion were analysed following
transfection of the construct into Neuro2A cells (an established cell
line derived from a spontaneous neuroblastoma in an albino strain
A mouse), where a correct processing of the proCRH to mature
peptide was previously demonstrated [13]. Neuro2A cells of
Figure 1. Family pedigree of the proband and electropherograms showing the identified mutation. On the left, the pedigree of the
Italian ADNFLE family is shown. The arrow points to the proband. On the right, sequence electropherogram including the identified mutation is
shown. The patient is a heterozygote for a missense mutation (p.Pro30Arg). The proband’s mother is not a carrier of the mutation and the father
genotype is unknown doing to the unavailability of his DNA. RBD: REM sleep behavior disorder.
doi:10.1371/journal.pone.0061306.g001
CRH Mutation and ADNFLE
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e61306
commercial source (Sigma Aldrich) were grown according to
standard procedures. Cultures were carried out in DMEM
containing 10% fetal bovine serum (FBS), 100 U/ml penicillin,
100 mg/ml streptomycin and 8 mM glutamine. Cell cultures were
maintained in 5% CO2 humidified atmosphere at 37uC (Thermo
Scientific, Waltham, MA, USA).
Transient transfections were performed using the X-
tremeGENE 9 DNA Transfection Reagents (Roche, Mannheim,
Germany). Cells were plated at a density of 6.56105 cells per
94 mm plate. Briefly, 5 mg of each expression vectors (pCDNA3X-
CRH wt, pCDNA3X-CRHP30R) were transfected using a 3:1
ratio between X-tremeGENE 9 and DNA. Transfections were
performed 24 h after plating and all procedures were according to
the manufacturer standard protocol.
Preparation of cell extracts and cell fractionation
Total lysate extracts were obtained by washing cells in cold
phosphate buffered saline (PBS) solution (10 mM K2HPO4,
150 mM NaCl, pH 7.2) and subsequent lysis with Sample Buffer
(50 mM Tris-HCl pH 6.8, 0.4% SDS, 4% Glycerol, 1% b-
mercaptoethanol, 0.02% bromophenol blue). The extracts were
passed through a syringe needle and then denatured at 100 uC for
5 min.
Cell fractionation were carried out using the Subcellular Protein
Fractionation Kit for Cultured Cells (Thermo Scientific) according
to the suppliers instructions. The kit allows separation and pre-
paration of cytoplasmic, membrane, nuclear soluble, chromatin-
bound and cytoskeletal protein extracts from mammalian cultured
cells.
Protein concentration of samples was determined by BCA assay
using Pierce BCA Protein assay kit (Thermo Scientific).
Both total lysate and subcellular extracts were used to perform
Western blot analysis.
Each experiment has been repeated at least three times.
SDS-PAGE and Western blot
SDS-PAGE and Western-blot were carried out by standard
procedures. PVDF ImmobilonTM P (Millipore Billerica, MA,
USA) membranes were blocked for 30 min in PBS, containing 5%
(w/v) dried milk. Membranes were probed overnight in PBS
containing 5% dried milk with anti-CRH rabbit polyclonal
antibody (1:800) (Source Biosciences, Nottingham, UK).
As a control we used anti-a-Tubulin mouse antibody (1:10000)
in TBS-T (50 mM Tris-HCl, 150 mM NaCl, pH 7.5, 0.1%
Tween20) containing 5% dried milk and anti-calnexin rabbit
antibody (1:2000) in PBS containing 1% dried milk. Membranes,
probed with mouse antibodies, were incubated for 1 h with an
anti-mouse horseradish peroxidase-conjugated IgG (1:10000) (Cell
Signalling Technology, Danvers, MA, USA) in PBS, 0.1% (v/v)
Tween20 containing 1% (w/v) dried milk, while membranes
probed with rabbit antibodies were incubated for 1 h with an anti-
rabbit horseradish peroxidase-conjugated IgG (1:10000) (Cell
Signalling Technology) in PBS containing 5% (w/v) dried milk.
Detection of antibody binding was carried out with ECL
(Amersham GE Healthcare, Uppsala, Sweden), according to the
manufacturer’s instructions. Protein levels were quantified by
densitometry of scanned not saturated X-ray films using the NIH
Image-based software Scion Image (Scion Corporation).
cDNA synthesis and real-time quantitative PCR
Total RNA was extracted from cultured cells by means of the
RNeasy mini kit (QIAGEN) and eluted in water. Synthesis of first-
strand cDNA was carried out using Quantitec Reverse Transcrip-
tion kit (QIAGEN), using 1 mg of total RNA as template. The first-
strand cDNA was used as a template for real-time PCR using a
human CRH specific primer pair (Fw 59-GGGAACCTCAA-
CAAGAGCCC-39 and Rv 59AACACGCGGAAAAAGTTGGC-
39) and SYBR Green technology (Applied Biosystem). b-actin was
used as housekeeping gene (Fw 59-CGACAGGATGCAGAAG-
GAG-39, Rv 59-ACATCTGCTGGAAGGTGGA-39). The rela-
tive expression levels were calculated with the 22 [DC(t)] method.
ELISA
Indirect enzyme-linked immunosorbent assay (ELISA) was
performed to evaluate the presence of mature CRH in the cell
culture media. The samples were diluted in 100 mM carbonate/
bicarbonate buffer pH 7.4, pipetted into a microtiter plate 50 mL/
well and incubated 2 h at room temperature. After then the
coating solution was removed and the wells were washed three
times with PBS buffer containing 0.05% Tween. The remaining
protein-binding sites were blocked with PBS containing 1% BSA
and incubated for 2 h at room temperature. After washing twice
with PBS buffer, wells were probed overnight in PBS containing
5% (w/v) BSA with anti-CRH rabbit polyclonal antibody (1:1000)
(Source Biosciences).
Then samples were probed with an anti-rabbit horseradish
peroxidase-conjugated IgG (1:10000) (Cell Signalling Technology)
in PBS containing 5% (w/v) BSA.
Detection of antibody binding was carried out with TMB
(3,39,5,59-tetramethylbenzidine) solution for 20 min. The reaction
was stopped adding equal volume of 2 M H2SO4. The
concentration of CRH was determined by comparing the O.D.
of the samples to the standard curve at a wavelength of 450 nm 6
2 nm. Our samples were composed by media collected from
cultures of cells transfected with the vector expressing either the
wild-type or the mutant CRH precursor.
Immunofluorescence and confocal analysis
Neuro2A cells were plated onto coverslips (2.56104 cells/
coverslip) and grown for 24 h before transfection. Cells were
transfected with X-Treme GENE 9 (Roche) and constructs coding
for the wild-type or the mutated form of human CRH using a 3:1
ratio. 24 and 48 h after transfection, cells were fixed for 20 min in
3% (w/v) paraformaldehyde in PBS and quenched for 30 min
with 50 mM NH4Cl in PBS. Permeabilization was carried out by
incubating the cells in the presence of 0.3% (w/v) saponin in PBS
(7 min for 3 times). Cells were then doubly stained with anti-CRH
rabbit polyclonal antibody (Source Biosciences, 1:200). Cells were
also incubated with anti-GM130 polyclonal antibody BD Biosci-
ences, 1:250) for Golgi visualization.
After extensive washes, cells were incubated with Alexa-488
anti-rabbit conjugated antibody (1:200) and Alexa-555 anti-mouse
conjugated antibody (1:500). All antibodies were from Invitrogen
(Carlsbad, CA, USA). Incubations and washes were carried out at
room temperature in PBS, 0.3% saponin. Finally, cells were
incubated for 15 min with the nuclear marker TO-PRO-3 iodide
1:300 (Molecular Probes, Invitrogen UK Ltd Paisley, UK).
Confocal microscopy was performed using a Leica Mod. TCS-
SP2 (Leica Microsystem, Milano, Italy). Image processing was
performed with Leica Confocal Software (LCS) and Adobe
Photoshop Software (Adobe Systems Incorporated, San Jose,
CA, USA). Protein colocalization signals were quantified by
densitometry.
Statistical analysis
Statistical analyses were performed by two-way ANOVAs with
genotype (either mutant or wild-type), time (24 h or 48 h) and
their interaction as predictors. In no case the removal of the
CRH Mutation and ADNFLE
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non-significant interaction term altered the significance of main
terms. We therefore present the results of the full models only.
Robustness of the results to possible deviations from the
assumptions of ANOVA test was checked by a randomization
procedure (unrestricted resampling of observations for the main
terms, unrestricted sampling of residuals for the interaction term,
5000 resamples in both cases; see [14]). Results from the
randomization procedure always confirmed those of parametric
tests and were therefore not reported for brevity. Post-hoc tests
were also performed with the multiple comparison method.
Colocalization data were analyzed by a t-test. All the analyses were
performed by R 2.15.1 [15].
Results
Mutational screening
Sequencing of the coding region, intron-exon boundaries and
UTRs of CRH revealed that the proband is a heterozygote for a
missense mutation (Fig. 1). Nucleotide numbering from here
onward is according to cDNA position (GenBank accession
number NM_000756.2 starting from the first nucleotide of the
ATG start codon); amino acid positions are indicated within the
signal peptide and the prosequence.
The mutation consists of a C.G transversion at cDNA position
89 (c.89C.G), which leads to a non-conservative Pro to Arg
change at position 30 (p.Pro30Arg according to the Human
Genome Variation guidelines) in preproCRH. This mutation was
found in the heterozygous state also in the affected proband’s
sister, while it was absent in the healthy mother (Fig. 1). The
father, who was affected from REM sleep behaviour disorder
(RBD) and was probably a carrier of the mutation, was
unfortunately dead thus it was impossible to verify the presence
of the mutation.
The mutation was not present in 100 ancestry-match control
samples and it was also not found in public databases. The
aminoacid change in CRH was predicted to be pathogenic
(PolyPhen2) [16] and affected a highly evolutionary conserved
aminoacid.
Expression and subcellular localization of wild-type and
p.Pro30Arg CRH precursor in Neuro2A cells
To evaluate the effect of the identified missense mutation in the
production and secretion of CRH, Neuro2A cells, which express
only a basal level of endogenous CRH and which are reported to
be able to correctly process the prohormone to the mature protein
[13], were transiently transfected with plasmid coding either the
wild-type or the mutant protein.
Cells lysates were prepared 24 h after transfection and the CRH
precursor content was measured by SDS-PAGE Western blot.
Results indicated a lower intracellular protein level in cells
expressing mutant CRH as compared to those expressing the
wild-type form (data not shown).
No significant differences between the wild-type and mutant
cDNA transcription levels were observed in RealTime PCR
(Fig. 2A), thus suggesting that the above reported differences were
not due to a difference in gene expression.
To test whether the reduction in protein level was generally
distributed overall the cell or related to a particular subcellular
location, CRH precursor content in extracts from cytoplasmic,
membrane, nuclei and cytoskeleton fractions was measured 24 h
and 48 h after the transfection.
Statistical analyses showed a significantly lower level of CRH-
precursor in all above mentioned fractions of cells expressing
mutant CRH in respect to the wild-type, independently of time
(F1,8 $ 6.646, p # 0.033, see Figure 2B for details). Moreover,
between 24 h and 48 h, different patterns of variation in the
membrane fraction’s CRH level were found between the wild-type
and the mutant (effect of the genotype by time interaction:
F1,8 = 6.618, p = 0.033). In particular, post-hoc tests indicated that
cells expressing the wild-type CRH precursor had significantly
higher protein levels than those expressing the mutant form in the
membrane fraction 24 h after transfection (t = 5,274, p = 0.002),
while 48 h after transfection no significant differences were
detected (t = 1.636, p = 0.360). Protein levels of wild-type CRH
precursor decreased significantly between 24 h and 48 h
(t =23.676, p= 0.020) unlike CRH mutant levels (t =20.038,
p.0.999; Figure 2B).
A difference in CRH intracellular distribution was observed also
by immunofluorescence imaging 48 h after transfection. In
particular, a statistically significant (t21 = 3.406, p = 0.003) higher
co-localization with the Golgi apparatus was observed in cells
expressing the mutant CRH precursor protein (Fig. 3). The
densitometric analysis showed that the average value of the
colocalization signal for cells transfected with the mutant plasmid
was double than that observed for the wild-type.
Secretion of CRH in cell culture media
To compare the ability to secrete the hormone of the Neuro2A
cells transfected with either wild-type or mutant construct, CRH
levels in the culture medium were evaluated 24 h and 48 h after
transfection through ELISA. A significant difference in protein
levels were observed only at 24 h (F1,4 = 37.39; p = 0.004). In
particular, at that time protein levels resulted to be significantly
lower in media of cells transfected with the mutant construct than
with the wild-type (t = 7.796, p = 0.004) (Fig. 2C).
Discussion
In this article we report a novel mutation (p.Pro30Arg) within
the CRH gene cosegregating with sleep disorders (i.e. ADNFLE
and RBD) and detected in an Italian family. The mutation was
found in heterozygosis in two individuals affected by ADNFLE
and it was probably inherited from the dead father (who was
reported to suffer of a not precisely defined RBD) being absent in
the healthy mother. Unfortunately the DNA of two healthy
brothers of the probands was not available. However, even if one
of them would be a carrier of the mutation we would have not
been able to exclude its involvement in the pathogenesis of the
disease due to its well known reduced penetrance. The mutation
causes the change of a highly conserved Proline to an Arginine
located in the hormone pro-sequence region which is encoded by
the exon 2 of the gene. The CRH hormone is in fact firstly
produced as a 196-amino acid (aa)-long prepro-CRH, in which the
first 26 aa represent the signal peptide, cleaved in the rough
endoplasmic reticulum to generate pro-CRH-(27—196) [13].
Endoproteolytic processing of pro-CRH within the trans-Golgi-
network and secretory granules generates the mature hormone.
This is the first mutation described in the coding region of the
CRH gene and associated to ADNFLE. Up to now two variants in
the promoter of this gene were reported in both familial and
sporadic cases of NFLE altering the level of the gene expression
[2]. The here reported mutation instead, due to its own location,
has no effect on the gene transcription levels while it appears to
alter the ability of the cell to promptly produce, process and
secrete the mature hormone. In particular, a reduced level of
CRH immunoreactive peptides was detected both in lysate
extracts and in all subcellular fractions derived from cells
expressing the mutant cDNA. This could be observed both at
CRH Mutation and ADNFLE
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24 h and 48 h after transient transfection. Moreover, our results
showed that in the membrane fraction the mutant-protein levels
did not vary significantly in the course of time while a significant
reduction could be observed in cells expressing the wild-type form.
The lack of variation of mutant-protein levels between 24 h and
48 h in this cellular fraction may derive from a functional aspect,
arising from a different cellular metabolism, or result from a
constitutive low level of the mutant protein expression ab initio.
As far as the reduction in protein levels among the two different
genotypes, two possible hypotheses could be put forward: the
translation on ribosomes of the mutant mRNA is impaired or the
mutant protein is somehow degraded more than the wild-type
form. The first hypothesis appears to be less convincing owing to
the fact that the mutation is not at the 59 end of the mRNA and is
located far from the translation starting codon. An in silico analysis
of the mutation effects performed with Peptide Cutter Tool [17]
argued in favor of the second hypothesis owing to the fact that the
mutation resulted to introduce a putative cleavage site for three
additional proteases (Arg-C Proteinase, Clostripain, Trypsin).
Moreover, the half-life of the CRH precursor is very brief thus
we could postulate that the mutant protein could not be promptly
processed in the rough endoplasmic reticulum and in Golgi
apparatus, and this delay could result in a higher level of protein
degradation. This delay in processing in presence of the
p.Pro30Arg could be related to the identified difference in the
membrane fraction’s patterns of protein levels: cells expressing the
wild-type protein are able to produce and secrete the CRH more
quickly than those expressing the mutant form.
The hypothesis of a delay in post-translational protein
processing is supported by imaging results showing a higher
colocalization between CRH immunoreactive proteins and Golgi
apparatus at 48 h after the transfection in cells expressing the
mutant than in those expressing the wild-type protein.
Finally, our results demonstrated that levels of secreted CRH
were significantly lower for cells expressing mutant CRH at 24 h
after the transfection while an apparent recovery could be seen at
48 h when no significant differences were measured. A possible
explanation of this recovery could be that, while the wild-type
protein is mainly secreted within 24 h, only a reduced amount of
the mutant protein (which is less abundant in the cell and
‘‘blocked’’ in the Golgi apparatus) is able to be processed and
released rapidly. Instead, the mutation delays this process, thus the
majority of the mutant protein is secreted later and it is measured
at 48 h in our experiments as the sum of both the delayed mutant
protein and the normally produced one. This additive effect masks
the intrinsic differences in secretion levels of the two population of
cells transfected with different plasmids. It is worthwhile to note
that the protein structure of the released mature hormone is the
Figure 2. Ability to express CRH in Neuro2A cells transiently transfected with wild-type or mutant preproCRH construct. A) CRH
levels of expression detected by realtime quantitative PCR in not transfected (NT) or transfected cells (wt or p.Pro30Arg) at three different times: 24 h,
48 h and 72 h. Each bar represents the mean6 S.E.M. (n= 3) of mRNA levels normalized to the basal CRH expression in Neuro2A cells (NT values) and
to a housekeeping control gene (b-Actin). * t =23.676 and p=0.020 compared with wt at 24 h; ** t = 5.274 and p=0.002 compared with wt at 24 h.
B) Densitometric analysis of CRH immunoreactive proteins in subcellular fractions of the Neuro2A cells. Each bar represents the mean 6 S.E.M. (n= 3)
and protein content is expressed in arbitrary units. C) Levels of secreted CRH protein measured by ELISA. The ability of cells to secrete the CRH
hormone was evaluated by measuring the protein level in cultured media of cells transfected either with the wild-type or the mutant construct at
24 h or 48 h after the transfection. Each bar represents the mean 6 S.E.M. (n= 2) and protein content is expressed as % in respect to the mean value
of wt 24 h (assumed equal to 100%).* t =27.403 and p= 0.005 compared with wt at 24 h; ** t = 7.796 and p= 0.004 compared with wt at 24 h.
doi:10.1371/journal.pone.0061306.g002
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same in the two cases. The mutation, in fact, resides outside the C-
terminal domain that produces the mature CRH, thus the
incorrect amino acid is intracellularly removed. This location
excludes the possibility that the mutation influences CRH
properties as a neurotransmitter. Since the mature mutant
hormone is identical to the wild-type in structure, it is also very
unlikely that its degradation and/or uptake may be affected.
Overall the reported results suggest an impairment in the ability
to promptly release the hormone in the presence of the
p.Pro30Arg mutation in the pro-sequence. This impairment,
which is however partially mitigated in our patients by the fact that
the mutation was always found in heterozygosis, could be related
to an altered capability of patients to respond quickly to stress
agents and this would result in an impaired HPA axis cascade as
well as an impairment in the CRH-mediated sleep/arousal cycle
regulation. Unfortunately, hormonal dosages in patients positive to
the mutation were not feasible because they were already under
pharmacological treatments and it is well known that drugs may
alter the hormonal levels. A stop of the pharmacological treatment
before the hormonal evaluation would have raised ethical
questions. Moreover, the peripheral cortisol levels could not
reflect those in the CNS.
Although a functional effect of the mutation was demonstrated
by our results, a direct role of the p.Pro30Arg in NFLE
pathogenesis has still to be proved. This could be done only by
the identification of new ADNFLE families with the mutation
cosegregating with the disease or by the development and study of
specific transgenic mouse models. However, this is the third
variant detected in the CRH gene of NFLE/ADNFLE patients
causing the production of altered levels of the hormone and this
recurrence suggests that individuals with such an altered hormone
level could be more prone to develop the disease. In fact, it was
previously reported that this hormone promotes wakefulness and
impairs sleep in a dose-dependent way [18] and it was also
reported as a factor that increases susceptibility to seizures, being
however not the direct cause of the seizure onset: altered CRH
levels could modify the sigma activity, thus increasing the
susceptibility to seizures as well as to abnormal sleep spindles
timing. Moreover, the involvement of CRH, which has a much
higher proconvulsant effect in young people [19] could be related
to the fact that a complete remission of the disease was reported
for some patients.
In conclusion, the present paper strengths the importance of a
mutation screening of the whole CRH gene in patients affected by
NFLE/ADNFLE.
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Figure 3. Confocal images of Neuro2A cells transfected with the wild-type or the mutant construct. To investigate intracellular
distribution of CRH, cell were fixed in PFA and probed with mouse polyclonal anti-GM130 (red) for Golgi visualization and rabbit polyclonal anti-CRH
(green) antibodies.
doi:10.1371/journal.pone.0061306.g003
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